Company: PFSA
Filing Date: 2025-05-09
Form Type: S-4/A
Source: 0001213900-25-041151
Chunk: 205

Company: Profusa, Inc.
Filing Date: 2025-05-09
Form: S-4/A
Chunk 205
---
92 Additional Risks Relating to Ownership of New Profusa Common Stock Following the Business Combination If the perceived benefits of the Business Combination do not meet the expectations of investors or securities analysts or for other reasons, the market price of NorthView’s securities, prior to the Closing, or New Profusa’s securities, following the Business Combination, may decline. If the perceived benefits of the Business Combination do not meet the expectations of investors or securities analysts, the market price of NorthView’s securities prior to the Closing may decline. The market values of New Profusa’s securities at the time of the Business Combination may vary significantly from their prices on the date the Merger Agreement was executed, the date of this proxy statement/prospectus, or the date on which NorthView’s stockholders vote on the Business Combination. In addition, following the Business Combination, fluctuations in the price of New Profusa’s securities could contribute to the loss of all or part of your investment. Prior to the Business Combination, there has not been a public market for Profusa’s securities. Accordingly, the valuation ascribed to Profusa may not be indicative of the price that will prevail in the trading market following the Business Combination. If an active market for New Profusa’s securities develops and continues, the trading price of New Profusa’s securities following the Business Combination could be volatile and subject to wide fluctuations in response to various factors, some of which are beyond New Profusa’s control. Any of the factors listed below could have a negative impact on your investment in New Profusa’s securities and New Profusa’s securities may trade at prices significantly below the price you paid for them. In such circumstances, the trading price of New Profusa’s securities may not recover and may experience a further decline. Factors affecting the trading price of New Profusa’s securities may include: •changes in financial estimates by New Profusa or by any securities analysts who might cover its stock; •proposed changes to laws in the U.S. or foreign jurisdictions relating to New Profusa’s business, or speculation regarding such changes; •conditions or trends in the diagnostic, medical device or biotechnology industries; •stock market price and volume fluctuations of comparable companies; •announcements by New Profusa or its competitors of significant acquisitions, strategic partnerships or divestitures; •significant lawsuits or announcements of investigations or regulatory scrutiny of its operations or lawsuits filed against New Profusa; •recruitment or departure of key personnel; •investors’ general perception of New Profusa’s business or management; •trading volume